LeonaBio (LONA) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
18 Mar, 2026Opening remarks and agenda
Meeting called to order by the Chairperson, with board members, senior management, legal counsel, and Inspector of Election present.
Procedures for orderly conduct and voting outlined at the start.
Specific resolutions to be voted on
Approval of issuance of 5,502,402 shares of common stock via Surmodics pre-funded warrant exercise under Nasdaq Rule 5635(a)(2).
Approval of issuance of shares to Surmodics if beneficial ownership exceeds 19.99% post-exercise, per Nasdaq Rule 5635(b).
Approval of issuance of shares to Perceptive Advisors if beneficial ownership exceeds 19.99% post-exercise, per Nasdaq Rule 5635(b).
Approval of the 2026 Equity Incentive Plan.
Amendment to increase authorized shares of common stock.
Authorization to adjourn the meeting if necessary to solicit additional proxies.
Corporate governance
Only stockholders of record as of January 27, 2026, were eligible to vote.
Quorum confirmed with majority of shares present or represented by proxy.
Inspector of Election appointed and oath filed with meeting minutes.
Latest events from LeonaBio
- Virtual annual meeting to vote on directors, auditor, and executive pay, all board-recommended.LONA
Proxy filing11 May 2026 - Proxy covers director elections, auditor ratification, compensation, and ESG oversight.LONA
Proxy filing11 May 2026 - Q1 2026 net loss rose to $32.9M as R&D spending increased; cash covers 12 months, more funding needed.LONA
Q1 20267 May 2026 - Lasofoxifene plus abemaciclib shows strong promise for ESR1-mutated metastatic breast cancer.LONA
Status update30 Apr 2026 - Registering 5.5M shares for resale; proceeds from warrant exercise support drug pipeline.LONA
Registration filing31 Mar 2026 - 58.5M shares registered for resale; warrant exercises could yield over $146M for clinical programs.LONA
Registration filing31 Mar 2026 - Secured lasofoxifene license, raised $90M, and advanced clinical pipeline amid higher R&D spend.LONA
Q4 202526 Mar 2026 - Proposal 6 is now routine, enabling discretionary broker voting at the March 2026 meeting.LONA
Proxy Filing10 Mar 2026 - Shareholders to vote on major share issuances, new equity plan, and increased authorized stock.LONA
Proxy Filing23 Feb 2026